-
Mashup Score: 5Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma - 4 month(s) ago
Older patients with multiple myeloma (MM) exhibit wide heterogeneity in their baseline physiologic and functional status, which demands an individualized treatment approach based on biological rather than chronological age. Various frailty scores have been developed for older patients with MM, but they are underutilized in clinical trials and in practice. Older patients with MM are underrepresented in therapeutic clinical trials, and treatment recommendations are currently derived from clinical trials of transplant-ineligible patients. This article provides a summary of phase II and III clinical trials in transplant-ineligible patients with newly diagnosed MM, highlighting outcomes in patients aged ≥75 years and frailty-based outcomes. The data available thus far show that triplet regimens are more efficacious than doublets in older patients but may be associated with higher toxicity. DRd (daratumumab/lenalidomide/dexamethasone) and VRd (bortezomib/lenalidomide/dexamethasone) are good
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Association of Intellectual and Developmental Disabilities With Worse Outcomes After Surgical Treatment of Cancer - 4 month(s) ago
Background: Patients with intellectual and developmental disabilities (IDD) face unique challenges resulting in disparities in their health care. We sought to define the effect that IDD had on achievement of a “textbook outcome” (TO) following a cancer operation among a nationally representative cohort of patients. Methods: Data on patients who underwent surgery for a malignant indication, including lung, breast, liver, biliary tract, pancreas, and colorectal, between 2014 and 2020 were extracted from the 100% Medicare Standard Analytical Files database. The association of IDD with TO (defined as the absence of postoperative complications, extended length of stay, 90-day readmission, and 90-day mortality), expenditures, and discharge status was assessed using multivariable logistic regression. Results: Among 500,472 Medicare beneficiaries, 4,326 (0.9%) with IDD had a cancer diagnosis (breast, n=481; lung, n=419; hepatobiliary, n=194; pancreas, n=145; colorectal, n=3,087). Although over
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Association of Intellectual and Developmental Disabilities With Worse Outcomes After Surgical Treatment of Cancer: https://t.co/lfyQLt5qzC #hsronc @timpawlik @vivanresende6 @OhioStateSurg @OSUWexMed https://t.co/79rM2N1R96
-
-
Mashup Score: 5JNCCN - 4 month(s) ago
JNCCN
Source: jnccn.orgCategories: General Medicine News, Onc News and JournalsTweet-
The August issue of @JNCCN is now available online! Featured: @NCCN Guidelines on Adolescent and Young Adult (#AYA) Oncology, insights into recent updates to #NCCNGuidelines for #Survivorship, and more! https://t.co/8t8aPaSww2 #AYAcsm #survonc https://t.co/WiN2kzpsqA
-
-
Mashup Score: 0Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity - 4 month(s) ago
Background: Although the need to reduce the impact of financial toxicity among patients with cancer is widely acknowledged, few interventions have been developed to address this issue. We tested a novel, multiphase, patient-centered financial navigation (FN) intervention at a large academic medical center. Methods: We developed a financial toxicity screening tool consisting of the Comprehensive Score for Financial Toxicity (COST) measure plus several additional items based on patient feedback. After systematizing the screening process, 50 patients from the North Carolina Basnight Cancer Hospital were enrolled in the FN intervention following a positive screen for financial distress (COST score <23). The FN intervention involved one-on-one consultations with a trained financial navigator and included an initial comprehensive intake appointment to determine patient eligibility for financial assistance and follow-up appointments to discuss paperwork and application(s) status. We assessed
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related #FinancialToxicity: https://t.co/VsCdvkErvA https://t.co/7jidY44EH9
-
-
Mashup Score: 0Evaluation of Socioeconomic and Racial/Ethnic Disparities in All-Cause Mortality in Adolescents and Young Adults With Cancer - 4 month(s) ago
Background: Adolescent and young adult (AYA) patients with cancer have historically been understudied. Few studies have examined survival disparities associated with racial/ethnic and socioeconomic status (SES) and do not account for the influence of insurance status and access to care. We evaluated the association of SES and race/ethnicity with overall mortality for AYA patients who were members of an integrated health system with relatively equal access to care. Methods: AYA patients diagnosed with the 15 most common cancer types during 2010 through 2018 at Kaiser Permanente Southern California were included. Neighborhood Deprivation Index (NDI) quartile (Q1: least deprived; Q4: most deprived) was used as a measure of SES. Mortality rate per 1,000 person-years was calculated for each racial/ethnic and NDI subgroup. Multivariable Cox model was used to estimate hazard ratios (HRs) for all-cause mortality adjusting for sex, age and stage at diagnosis, cancer type, race/ethnicity, and ND
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Evaluation of Socioeconomic and Racial/Ethnic #Disparities in All-Cause Mortality in Adolescents and Young Adults With Cancer: https://t.co/vwdE3bj9o4 #cancerdisparities #healthequity #hsronc #ayacsm https://t.co/L1qlchTUSY
-
-
Mashup Score: 0Sympathetic Blockade for Pain Associated With Nonaxial Bone Lesions in Patients With Cancer: An Uncontrolled Cohort - 4 month(s) ago
Background: Cancer-related bone pain remains a prevalent and frequently incapacitating ailment. Although conventional approaches effectively alleviate pain in most individuals, a subset of patients may continue to experience intractable pain. Current recommendations for treating cancer-related bone pain include oral analgesics and multimodal adjuvants, radiation therapy, and, in selected cases, intrathecal therapy. Cancer-related bone pain is mediated by a proliferation of sensory and sympathetic fibers. Thus, we believe that this pain can be successfully managed with minimally invasive sympathetic blockade (SB). Methods: In a retrospective observational cohort, we reviewed patients who underwent single-shot SB for uncontrolled cancer-related bone pain despite receiving opiate analgesics and other interventions. We documented the Edmonton Symptom Assessment Scale (ESAS) ratings, the numeric rating scale (NRS) pain scores, and the morphine equivalent daily dose (MEDD) before and after S
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Sympathetic Blockade for Pain Associated With Nonaxial Bone Lesions in Patients With Cancer: An Uncontrolled Cohort, by @CroldanMD et al of @MDAndersonNews: https://t.co/7YMnRDMZ73 #CancerPain https://t.co/JVHsB3O6Ve
-
-
Mashup Score: 9NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024 - 4 month(s) ago
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
This month's #NCCNGuidelines Insights address the changing #ovariancancer treatment landscape & summarize current recommended PARP inhibitor use in the @NCCN Guidelines for Ovarian/Fallopian Tube/Primary Peritoneal Cancers https://t.co/yjRh4cjPnw #gyncsm Earn free #CME #CNE #CPE https://t.co/L0CHWWpVlg
-
-
Mashup Score: 3Racial and Ethnic Disparities in the Time to Ovarian Cancer Surgery in Patients at an Integrated Health Care Delivery System - 4 month(s) ago
Background: Disparities in ovarian cancer survival for African American women are multifactorial. We evaluated racial and ethnic differences in time to ovarian cancer surgery in members of an integrated health care system. Patients and Methods: In this retrospective cohort study, we identified women diagnosed with invasive epithelial-type ovarian cancer between January 1, 2008, through December 31, 2014, at an integrated health care system in the United States. We extracted data on cancer-related variables and sociodemographic variables from the health care system’s cancer registry and electronic health records. We included patients who received ovarian cancer surgery without neoadjuvant chemotherapy. We defined time to surgery as the number of days between diagnostic imaging study and surgery. We used Cox proportional hazards regression to evaluate crude and adjusted association of race and ethnicity with time to surgery. Results: Of 872 patients included, 55.1% were non-Hispanic Whit
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Racial and Ethnic #Disparities in the Time to #OvarianCancer Surgery in Patients at an Integrated Health Care Delivery System: https://t.co/yLqqhm8PPX #CancerDisparities #HealthDisparities #HealthEquity https://t.co/rYB44VCIln
-
-
Mashup Score: 35Is it Time to Forget the 5-Fluorouracil Bolus? - 4 month(s) ago
“Is it Time to Forget the 5-Fluorouracil Bolus?” published on Oct 2024 by National Comprehensive Cancer Network.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @dr_yakupergun: Is it Time to Forget the 5-Fluorouracil Bolus? @JNCCN https://t.co/ZJ60TzcqWF https://t.co/8Avon2kdON
-
-
Mashup Score: 0Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study - 4 month(s) ago
Background: Mohs micrographic surgery (MMS) is a promising treatment modality for melanoma in situ (MIS). However, variations in surgical technique limit the generalizability of existing data and may impede future study of MMS in clinical trials. Methods: A modified Delphi method was selected to establish consensus on optimal MMS techniques for treating MIS in future clinical trials. The Delphi method was selected due to the limited current data, the wide range of techniques used in the field, and the intention to establish a standardized technique for future clinical trials. A literature review and interviews with experienced MMS surgeons were performed to identify dimensions of the MMS technique for MIS that (1) likely impacted costs or outcomes of the procedure, and (2) showed significant variability between surgeons. A total of 8 dimensions of technical variation were selected. The Delphi process consisted of 2 rounds of voting and commentary, during which 44 expert Mohs surgeons a
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Establishing Consensus for #Mohs Micrographic Surgical Techniques in the Treatment of #Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study: https://t.co/2ufvawnQhi @wesley_yu #skcsm https://t.co/1g4M03CfrF
-
Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With #MultipleMyeloma: https://t.co/60ohiHFooA #MMSM #gerinonc #hemeonc @siennadurbin @ryannipp @lundquistdebra https://t.co/UELVHB9g63